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Abstract
The objective of this scoping review is to summarize the current use of pharmacoki-
netics for tailoring prophylaxis in hemophilia patients switching between clotting 
factor products. Patients with hemophilia may require switching of clotting factor 
concentrates due to a variety of factors, but there have been perceived risks associ-
ated with switching, such as inhibitor development or suboptimal protection due to 
inadequate dosing while titrating treatment. Studies that look at patients switching 
from one clotting factor concentrate to another are categorized in terms of their 
primary and/or secondary objectives, notably biosimilarity and comparative pharma-
cokinetic studies and inhibitor development studies. Research on how best to switch 
concentrates with respect to dosing regimen are lacking, and currently a trial-and-
error approach is used for dosing the new factor concentrate. In the future, studies 
looking at the predictability of pharmacokinetics (PK) of a new factor concentrate 
based on individual PK knowledge of the original factor concentrate may offer clinical 
benefit by providing a safer switching approach and protocol.
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Essentials
• We assessed use of pharmacokinetics (PK) to tailor hemophilia prophylaxis when switching factor products.
• Identified studies primarily assessed biosimilarity and none used PK to inform switching.
• Switching is common based on a review of the WAPPS database for both factor VIII and IX.
• Evidence-based switching methods (eg, population PK) may improve dosing during switching.
1  | INTRODUCTION
The mainstay treatment of hemophilia involves administration of fac-
tor concentrates. In the past, factors VIII (FVIII) and IX (FIX) infusions 
were given during or soon after an acute bleed. This “on-demand” 
treatment decreased the number of patients with joint deformities 
but also significantly lowered their morbidity and mortality, ulti-
mately increasing their quality of life.1 This practice was soon to be 
[Article corrected on October 8, 2019, after 
first online publication on May 20, 2019: 
Investigator Claire Pouplard's name was 
misspelled as “Claire Poulard.” This has been 
corrected.]
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found suboptimal and a study by Aledort et al demonstrated that 
severe hemophilia patients without inhibitors undergoing an on-de-
mand treatment regimen still experienced reduced orthopedic out-
comes and increased deteriorated joints compared to those treated 
prophylactically.1,2 Prophylactic FVIII or FIX infusion has now been 
accepted as the standard for treating hemophilia patients well be-
fore joint damage is apparent.2‒6
Prophylaxis was conceived as repeatedly dosing the patient 
so as to obtain a measurable factor activity at all times. The chal-
lenge is that appropriate dosing regimens vary by patient and fac-
tor concentrate and should be individualized from a therapeutic 
and economic standpoint.6‒8 A “trial-and-error” approach is usu-
ally adopted, which involves using a typical prophylactic dosing 
regimen of 20 to 50 IU/kg, a dose that should provide the average 
patient with hemophilia with enough clotting factor to achieve 
the goal of a trough activity ≥0.01 IU/mL at 48 hours. However, 
this trial-and-error approach fails to account for individual phar-
macokinetic (PK) variability and, as per Iorio et al,9 may lead to 
suboptimal results.
The trial-and-error approach is used again when switching be-
tween factor concentrates. Common practice in this scenario is 
that either the dose is initially kept the same as before the switch 
and frequency is adjusted proportionally to the relative expected 
change in terminal half-life, or the dose and frequency tested in 
the pivotal studies are used in a first instance. Current guidelines 
suggest initiating extended half-life (EHL) products at the same 
dose as standard half-life concentrates but reducing the infusion 
frequency from 3 to 2 times weekly, and subsequently adjusting 
the dose based on a population pharmacokinetic (PopPK) ap-
proach.10,11 When a person with hemophilia switches between 
factor concentrates, the person is switching from a product with 
known PK, or at least with known outcomes (eg, dose required to 
reduce bleeding events), to one with unknown PK. Dosing a factor 
concentrate with unknown PK introduces the risk of underdosing 
or resource wastage, leading to increased risk of bleeds or unnec-
essary use of factor concentrate, respectively.
The decision to switch between factor concentrates depends on 
a variety of factors, and shared decision making while assessing the 
product's safety, efficacy, cost, and convenience is essential before 
introducing a new product. The availability of newer and safer FVIII 
concentrates has resulted in switching between different plasma-
derived or recombinant FVIII concentrates throughout the course of 
hemophilia treatment.12 Newer FVIII products report to have better 
PK in terms of longer half-life and thus may provide the advantage 
of fewer infusions.12 Other reasons for switching FVIII products may 
include cost savings, via a tender-based national plan coverage or 
otherwise, side effects, drug shortages, or hypersensitivity to the 
formulation.12
The optimal approach to dose selection when switching be-
tween factor concentrates remains unknown. To answer the 
question of what is known about the current use of PK for tai-
loring prophylaxis in people with hemophilia switching between 
factor concentrates, we conducted (1) a scoping literature review, 
searching for empirical evidence regarding optimal switching 
practice; and (2) a review of the Web-Accessible Population 
Pharmacokinetics Service–Hemophilia (WAPPS-Hemo) database 
available to explore the practice of switching as recorded in the 
real world. WAPPS-Hemo is a globally accessible online tool allow-
ing hemophilia treaters to estimate individual PK using a population 
PK approach based on a limited set of 2 to 3 plasma factor activ-
ity measurements and patient covariates (eg, age, weight, height). 
Patient covariates and PK profiles gathered by WAPPS-Hemo are 
deidentified and stored in a database. This database is available for 
research purposes to the members of the WAPPS-Hemo research 
network.13 The WAPPS-Hemo database provides information on 
current practices regarding product switching, as patients who 
have had >1 infusion recorded and have used >1 factor concentrate 
can be tracked within the system.
2  | METHODS
2.1 | Scoping review
The scoping review process followed these steps: (1) identify possi-
ble eligible studies; (2) select relevant studies; (3) chart the data; and 
(4) collate, summarize, and report the results, as proposed by Arksey 
and O'Malley.14 Following the PCC mnemonic,15 studies included 
hemophilia A or B patients (Population) switching between differ-
ent factor concentrates and including appropriate PK assessments 
(Concept) and without any limitation as to reasons for switching, so-
cioeconomic setting, and underlying health care system characteris-
tics (Context). Relevant studies were prospective in nature. A search 
strategy was developed using medical subject headings (MeSH). 
The literature search was independently performed in PUBMED 
(MEDLINE) in September 2018 by both JKY and ANE. Search terms 
included:
• (“Hemophilia A”[MeSH] OR “Hemophilia B”[MeSH] OR “Factor 
IX”[MeSH] OR “Factor VIII”[MeSH]) AND switch*
• (“Hemophilia A”[MeSH] OR “Hemophilia B”[MeSH]) AND “Cross-
Over Studies”[MeSH]
• (“Hemophilia A”[MeSH] OR “Hemophilia B”[MeSH]) AND 
“Pharmacokinetics”
• (“Hemophilia A”[MeSH] OR “Hemophilia B”[MeSH]) AND 
“Bioequivalence”
2.2 | WAPPS data review
For this review, all patients within the WAPPS-Hemo database were 
eligible for inclusion unless they had only 1 infusion or had only 1 
type of factor concentrate recorded on multiple occasions (Figure 1). 
The WAPPS user agreement allows reuse of the data for modeling 
and other research purposes, as described in the WAPPS study 
protocols, approved by the ethics boards at McMaster University 
and the University of Waterloo and registered in clinicaltrial.gov 
(NCT02061072, NCT03533504).
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3  | RESULTS
3.1 | Study selection
There were no research articles that specifically addressed the optimal 
approach to switching between factor concentrates. However, there 
were 39 peer-reviewed scientific articles that fell within our inclusion 
criteria (Figure 2). Reviewer 1 identified 39 and reviewer 2 identified 
38 that were identical to those selected by reviewer 1. Upon discus-
sion of the missing article, the reviewers decided to include it as it met 
the inclusion criteria. The 39 articles were the only studies that could 
provide treaters with methods for evidence-based switching using PK 
and were thus sorted based on their primary objective and appraised. 
Studies included bioequivalence or comparative PK studies, as well 
as inhibitor development studies during switching. All 39 studies are 
outlined in Table 1 (FVIII) and Table 2 (FIX).
3.2 | Biosimilarity/bioequivalence or comparative 
PK studies
Strictly speaking, the term bioequivalence should not be used for 
drugs produced by biotechnology; the term biosimilarity is more 
appropriate.16 However, bioequivalence was the terminology used 
in many of the studies as many were published prior to the 2014 
European Medicines Agency's guidance.16 Irrespective of the term 
used, studies assessing biosimilarity/bioequivalence did not usually 
enhance a switching protocol as a primary objective; however, their 
standardized dosing protocol allowed for comparison of individual 
PK profiles between the 2 brands under study. Thus, this section 
focuses on biosimilarity and comparative PK studies as both types 
compared population PK.
There were a limited number of studies that were biosimilarity 
or comparative PK studies (n = 34) (Tables 1 and 2). Biosimilarity 
refers to a lack of statistically significant differences in drug expo-
sure between 2 drug products. In multiple crossover studies, biosim-
ilarity was assessed by using a PK analysis to derive the maximum 
plasma factor activity (Cmax) following infusion and the area under 
the plasma concentration vs. time curve (AUC).17‒19 To establish bio-
similarity, the ratio of the logarithmic geometric mean values of Cmax 
and AUC must fall within the interval of 80% to 125% based on a 
90% confidence interval.17,18
All of the studies looking at comparing PK between 2 brands 
used PK end points, as suggested by the International Society of 
Thrombosis and Haemostasis and American and European reg-
ulatory bodies.12‒14 The test dose before and after the switch 
was almost always identical, usually with a weight-based dosing 
of 50 IU/kg of the factor concentrates. Using the same dose for 
different concentrates is a requisite for biosimilarity studies. All 
trials studied included a washout period of between 2 and 7 days 
before starting the trial and between different factor concen-
trates (Tables 1 and 2).
Biosimilarity/bioequivalence testing employs various types 
of statistics that are dependent upon the trial design. Most trial 
designs for biosimilarity testing of clotting factors employed a 
F I G U R E  1   Study flow diagram of 
WAPPS dataWAPPS Database
(n = 2785 subjects, 5152 infusions)
Subjects with >1 infusion
(n = 943 subjects, 3310 infusions)
Subjects with >1 infusion who
switched between factor concentrates
(n = 449 subjects, 1096 infusions)
1 subject associated with only 1 infusion
removed
(n = 1842 subjects, 1842 infusions)
Subjects who did not switch between factor
concentrates removed
(n = 494 subjectes, 2214 infusions)
591 switches between FVIII concentrates
(n = 394 subjectes, 985 infusions)
56 switches between FIX concentrates
(n = 55 subjectes, 111 infusions)
F I G U R E  2   Study flow diagram of 
PUBMED search
Records identified through database
searching (n = 788)
Records identified after duplicates
removed (n = 722)
Records excluded bacause of duplicates (n = 66)
Records identified after title screening
(n = 174)
Records excluded because of title screening (n = 548)
Studies excluded through abstract screening (n = 135)
Not crossover study (n = 119)
No PK evaluation (n = 6)
Not same patient on two products (n = 4)
Retrospective study (n = 4)
Not hemophilia A or B (n = 1)
Not using factor VIII or IX (n = 1)
Studies included from PUBMED
(n = 39)
•
•
•
•
•
•
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TA B L E  1   Summary of studies of hemophilia patients switching between factor VIII concentrates
Author Products
Dose  
(IU/kg)
No. of 
subjects 
screened 
for PK
Age range 
(mean) 
[median]
Minimum 
washout 
period (d) Primary objective
Biosimilarity or comparative PK studies
Di Paola17 (1) Advate 
(2) ReFacto
50 ± 5 21 19-72 
(35.8) 
[30]
3 Compare PK of ReFacto and Advate 
to establish bioequivalence
Dmoszynska31 (1) Prior FVIII 
product 
(2) Optivate
50 15 12-65 3 Investigate the PK of Optivate 
against other FVIII products
Fijnvandraat32 (1) rFVIII SQ 
(2) Octonativ M
50 12 17-64 
(34)
4 Compare PK of rFVIII SQ and 
Octonativ M
Kessler18 (1) ReFacto (2 formu-
lations) 
(2) Hemofil M
50 19 18-44 
(26.3)
5 Compare PK of the 2 formulations of 
ReFacto with Hemofil M to establish 
bioequivalence
Klamroth23 (1) Advate 
(2) rFVIII single-chain
50 27 19-60 
(35.4)
4 Compare PK parameters of rFVIII 
single-chain with full-length rFVIII
Martinowitz22 (1) Advate 
(2) N8
50 25 13-54 
(24)
4 Compare PK profiles of N8 and 
Advate to establish bioequivalence
Morfini33 (1) pdFVIII 
(2) rFVIII
25-56 
25-45
17 15-51 
(27.7) 
[24.9]
7 Compare PK profiles of 2 different 
classes of FVIII concentrates
Morfini34 (1) Recombinate 
(2) Hemofil M
50 47 6-62 
(26.4)
7 Compare PK profiles of Recombinate 
and Hemofil M
Morfini35 (1) Hemofil M 
(2) Monoclate HT 
(3) Monoclate P
25 10 - 7 Compare in vivo behavior among the 
3 products
Recht36 (1) Advate 
(2) Xyntha
50 24 12-60 
[24]
3 Demonstrate PK equivalence of 
Advate
Shah19 (1) Advate 
(2) Kovaltry
50 18 19-64 
(37.3) 
[36]
3 Compare PK profile of Advate and 
Kovaltry
Shirahata37 (1) BAY14-2222 
(2) Kogenate
50 5 15-43 
(32) 
[35]
5 Compare PK profile of BAY14-2222 
and Kogenate
Biosimilarity or comparative PK and inhibitor development studies
Abshire38 (1) Kogenate 
(2) rFVIII-FS
50 35 - 4 Compare PK and safety of Kogenate 
and rFVIII-FS
Coyle39 (1) rFVIII-FS 
(2) BAY 94-9027
25/50 
25/60
14 21-58 
(36.1)
3 Assess PK and safety of BAY 94-9027
Kulkarni40 (1) Prior FVIII 
product 
(2) Turoctocog alfa
- 
25-60
69 1-11 
(6.1)
3 Investigate safety, efficacy, and PK 
properties of turoctocog alfa
Mahlangu29 (1) Advate 
(2) rFVIIIFc
50 30 12-65 
[29]
- Evaluate safety, efficacy, and PK of 
rFVIIIFc
Meunier41 (1) Prior FVIII 
product 
(2) N8-GP
- 
60
24 0-11 
(6.0)
- Assess safety, efficacy, and PK of 
N8-GP
Mullins42 (1) Advate 
(2) BAX855
60 ± 5 31 1-11 
(6) 
[6]
- Determine immunogenicity, PK, 
efficacy, safety, and quality of life 
using BAX855
(Continues)
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2 × 2 × 2 crossover design. All biosimilarity and comparative PK 
studies observed average biosimilarity or average mean PK pa-
rameter differences and did not examine individual differences. 
Average biosimilarity assesses the PK between-subject variability 
(BSV) but does not directly assess the within-subject variability 
(WSV) over time. This may be reasonable given the a priori knowl-
edge that clotting factor concentrates demonstrate a high PK BSV 
and low WSV within 1 brand,6 and therefore the assessment of 
individual biosimilarity may not be necessary. Individual biosimi-
larity assesses for both the mean and variability of PK metrics and 
also the ratio of the 2 drug products on an individual basis and 
is recognized when both the average biosimilarity is established 
and the subject-by-formulation effect is insignificant.20 Average 
biosimilarity is important to assess mean PK differences in a pop-
ulation, but individual biosimilarity is highly impactful if the goal is 
to give prescribers confidence that biosimilarity will occur when a 
patient on one of the drug products is switched to the other.
In order for a drug to be therapeutically equivalent to another 
product, it requires the same active pharmaceutical ingredient 
(API), dosage form, strength, route of administration, and estab-
lished bioequivalence.21 Because clotting factors are not identical, 
as they are biologics, the PK BSV and WSV of the 2 brands may not 
hold; this is not the case with small molecules, where the API sys-
temic disposition is exactly the same between 2 drug products. As a 
result, the individual concentration-time profile of 1 factor concen-
trate can be different as compared to another factor concentrate of 
the same dose and frequency. If individual biosimilarity for 2 fac-
tor concentrates is established, they can be used interchangeably, 
and the PK of one factor concentrate is therefore predictive of the 
other. However, no study confirming individual patient biosimilar-
ity has been completed because it is difficult to achieve. In a study 
by Di Paola et al,17 patients who switched from Advate to ReFacto 
had very different individual PK parameters even though the av-
erage PK parameters were similar. Similar findings were observed 
with Martinowitz et al22 and Klamroth et al (Figure 3).23 The con-
clusion that 2 factor concentrates are bioequivalent does not mean 
that individuals will achieve the same concentration-time profile if 
the same dose is given. Likewise, similar average half-life between 
2 factor concentrates does not mean that the half-life between 2 
factor concentrates in any given individual will be similar; some in-
dividuals in Figure 3 had drastic differences in their PK across factor 
concentrates.
Author Products
Dose  
(IU/kg)
No. of 
subjects 
screened 
for PK
Age range 
(mean) 
[median]
Minimum 
washout 
period (d) Primary objective
Powell43 (1) Kogenate 
(2) Kogenate with 
pegylated liposome 
carrier (13 or 22 mg/
kg)
35 26 12-60 2 Investigate the safety, tolerability, 
bioavailability, pharmacokinetics, 
and pharmacodynamics of Kogenate 
with pegylated liposome barrier 
compared with standard Kogenate
Schwartz44 (1) Koate-HS 
(2) Recombinant 
FVIII
50 
20-40
17 - 7 Compare PK of plasma-derived and 
recombinant FVIII, assess efficacy 
of recombinant FVIII for home 
therapy, and assess efficacy for 
major surgical procedures and 
hemorrhage
Skotnicki45 (1) Vocento 
(2) Biostate-RP
50 17 18-57 
(36.5) 
[37]
4 Evaluate efficacy, safety, and PK of 
Voncento
Tiede46 (1) Prior FVIII 
product 
(2) N8-GP
- 
25/50/75
26 20-60 
[36.5]
4 Evaluate safety and PK of N8-GP 
in comparison with previous FVIII 
products
Young30 (1) Prior FVIII 
product 
(2) rFVIIIFc
50 60 1-11 
[5]
3 Evaluate safety, efficacy, and PK of 
rFVIIIFc
Inhibitor development studies
Hsu47 (1) Kogenate 
(2) Koate-HS
50 
-
12 23-53 
(37.8)
7 Evaluate safety and efficacy of 
Kogenate
Powell48 (1) Advate 
(2) rFVIIIFc
25/65 
25/65
19 23-61 
(34.6)
3 Evaluate safety and treatment-emer-
gent adverse events, development 
of antibodies, and laboratory 
monitoring
-, not specified; FVIII, factor VIII; pdFVIII, plasma-derived factor VIII; PK, pharmacokinetics; rFVIII, recombinant factor VIII; SQ, subcutaneous.
TA B L E  1   (Continued)
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No study involving switching between factor concentrates where PK 
was assessed used this information to predict a proper dosing regimen.
3.3 | Inhibitor development studies
The second type of study included patients serially taking at least 2 clot-
ting factor concentrates and had the objective of examining inhibitor 
development. Inhibitors are antibodies that neutralize clotting factors. 
These inhibitors are generally measured using the Nijmegen modifica-
tion of the Bethesda assay.24,25 Once inhibitors develop in a patient with 
hemophilia, it becomes much more difficult to treat them, resulting in 
an increase in morbidity and mortality in the affected population.24,26
Eighteen articles were identified in which their primary out-
come was focusing on inhibitor development after switching 
TA B L E  2   Summary of studies of hemophilia patients switching between factor IX concentrates
Author Products Dose (IU/kg)
No. of 
subjects 
screened 
for PK
Age range 
(mean) 
[median]
Minimum 
washout 
period (d) Primary objective
Biosimilarity or comparative PK studies
Alamelu49 (1) Alphanine 
(2) Benefix
50 9 15-73 
(41.2) 
[42]
7 Compare PK and pharmacodynamics 
properties of rFIX and pdFIX
Aznar50 (1) Immunine/
Octanine 
(2) FIX Grifols
65-75 25 12-38 
(23.1)
7 Compare pharmacokinetic profile of 
FIX Grifols to available Immunine 
or Octanine
Ewenstein51 (1) Benefix 
(2) Mononine
50 43 7-75 
[18.5]
7 Assess PK properties of the 2 prod-
ucts and address how variables 
affect in vivo recovery and half-life
Goudemand52 (1) FIX-SD-15 
(2) FIX-SD
60 11 - 10 Compare PK and coagulation activa-
tion markers of FIX-SD-15 and 
FIX-SD
Liebman53 (1) Alphanine 
(2) Mononine
40 12 - 7 Evaluate kinetics of FIX activity and 
protein
Lissitchkov54 (1) Benefix 
(2) Alphanine
65-75 22 15-45 
(27)
7 Compare PK between Benefix and 
Alphanine
Martinowitz55 (1) Benefix 
(2) IB1001
75 ± 5 32 15-64 5 Compare PK of IB1001 with those 
of Benefix and assess consistency 
of PK parameters
Thomas56 (1) Conventional FIX 
(2) High-purity FIX
75 19 - 7 Compare PK of high-purity FIX to 
conventional FIX
Windyga57 (1) Benefix 
(2) BAX326
75 ± 5 86 12-65 5 Characterize PK profile of BAX326 
and determine PK equivalence with 
Benefix
Biosimilarity or comparative PK and inhibitor development studies
Collins58 (1) Benefix 
(2) IB1001
75 ± 5 32 14.8-64.5 
(32.7) 
[29.9]
5 Establish PK noninferiority of 
IB1001 to Benefix, safety, and 
efficacy
Kenet59 (1) Prior FIX product 
(2) rFIX-FP
50 27 1-11 
(5.9)
- Evaluate PK, efficacy, and safety of 
rFIX-FP
Inhibitor development studies
Negrier60 (1) Prior FIX product 
(2) N9-GP
- 
25/50/100
20 21-55 
[30]
7 Determine safety by evaluating 
adverse events, antibody formation 
against FIX and N9-GP, physical 
examination, and clinical laboratory 
assessments
Powell61 (1) Benefix 
(2) rFIXFc
50 22 - 5 Determine annualized bleeding rate 
and development of inhibitors
Solano 
Trujillo62
(1) Immunine 
(2) BAX326
20-40 
75 ± 5
44 1-55 - Document exposure to Immunine 
and monitor for inhibitor 
development
-, not specified; FIX, factor IX; FVIII, factor VIII; pdFX, plasma-derived factor X; PK, pharmacokinetics; rFIX, recombinant factor X.
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factor concentrate products (Tables 1 and 2). It was previously 
thought that switching between factor concentrates was associ-
ated with an increased risk of inhibitor development,27 but recent 
studies have not shown consistent results.27,28 Although PK data 
may have been used in their statistical analysis, dosing regimens 
of each factor concentrate were not tailored based on PK. It was 
unclear whether the dose provided to the patient after switching 
was the optimal dosing regimen. Without knowledge of the dosing 
regimen in patients with hemophilia, it was also unclear whether 
the overdosing or underdosing of factor concentrate had an effect 
on inhibitor risk.
No inhibitor study that incorporated PK into its assessment was 
usable to inform methods for PK-tailored dosing.
3.4 | WAPPS‐Hemo data
As of September 15, 2018, there were >250 centers enrolled world-
wide with >3000 patients and >6300 infusions recorded. Infusion 
data was gathered for the purposes of determining the incidence of 
switching between factor concentrates.
A total of 2785 patients were taken from the WAPPS data plat-
form. The methodology is presented in Figure 1. Of the 2785 sub-
jects, 449 (16%) had infusions on ≥2 concentrates, with a total of 
647 switches. A summary of patient demographics is presented in 
Table 3.
In terms of FVIII products, there were a total of 394 patients and 
591 switches, accounting for 91% of total switches on WAPPS-Hemo. 
FVIII products, classified based on their molecular structure, are pre-
sented in Table 4. Of the 591 switches, the majority of the switches 
(n = 293) occurred from second- and third-generation recombinant 
full-length products (50%). There were 208 switches (35%) to EHL 
products, 73 switches (12%) to B-domain–deleted products, 229 
switches (39%) to another recombinant full-length product, and 81 
switches (14%) to plasma-derived products.
In terms of FIX products, there were a total of 55 patients and 
56 switches, accounting for 9% of total switches on WAPPS-Hemo. 
FIX products, classified based on their molecular structure, are pre-
sented in Table 5. Of the 56 switches, the majority of switches in 
WAPPS-Hemo occurred when switching from any FIX product to a 
recombinant Fc-fusion protein FIX product (n = 34), accounting for 
61% of all FIX switches.
4  | PHARMACOKINETIC TARGETS 
WHEN SWITCHING
While literature states the average of PK parameters (eg, half-life) 
when switching between factor concentrates, the range of such 
PK parameters can be highly variable. A study by Mahlangu et al29 
compared the terminal half-life of the recombinant FVIII Fc fusion 
protein, Eloctate, with a standard-acting FVIII concentrate (Advate) 
in a phase 3 study to determine the safety, efficacy, and PK. On 
average, the half-life of Eloctate was 1.5 times that of Advate at 
a dose of 50 IU/kg.29,30 This provides valuable information about 
the population, although it is clear from the breadth of factor con-
centrate brands being switched to and from, as identified in the 
WAPPS-Hemo database, that this type of study cannot be com-
pleted for all scenarios. A study by Young et al30 demonstrated that 
the individual half-life ratios of FVIII and Eloctate ranged from 0.79 
to 2.98. Such high half-life variability within an individual across 
FVIII products makes the application of the mean population dif-
ference irrelevant for use in individual dosing recommendations.
Of particular note was the lack of evidence that standard-acting 
factor concentrates have shorter half-lives than long-acting factor 
concentrates at the individual level. In the study by Klamroth et al,23 
the majority of patients had increased half-life when switching from 
F I G U R E  3   Example of individual PK 
parameters after switching
Baseline corrected
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Octocog alfa rVIII-SingleChain
Treatment group
Octocog alfa rVIII-SingleChain
Treatment group
Uncorrected
TA B L E  3   Demographics from WAPPS patients who have 
switched between factor concentrates
Parameter Whole cohort FVIII FIX
Subjects (n) 449 394 55
Switches (n) 647 591 56
Age (y) 1-78 1-78 2-68
Body weight (kg) 10-150 10-150 13-117
As of September 2018.
FVIII, factor VIII; FIX, factor IX; WAPPS, Web-Accessible Population 
Pharmacokinetics Service.
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octocog alfa to a recombinant FVIII single-chain concentrate; how-
ever, this was not the case for 4 of 27 subjects. The potential risk of 
assuming an increase in half-life when switching from a standard-
acting to a long-acting concentrate may lead to increased risk of 
bleeds due to underdosing. Without assessing individual PK param-
eters, the current approach of using population-level information to 
switch between factor concentrates may not yield expected results.
It would be desirable to estimate dosing regimens across a 
switch using an individualized approach. In an ideal scenario, where 
population PK tailored prophylaxis was widely adopted, patients 
planning on switching to a different factor concentrate would have 
information regarding their own PK estimates on their current 
factor concentrate. In theory, combining the knowledge of the in-
dividual's PK of a factor concentrate prior to the switch (origin con-
centrate) with the knowledge of the population PK characteristics 
of the concentrate after the switch (destination concentrate) may 
potentially lead to the ability to predict individual PK estimates of 
the destination concentrate. The accuracy and precision of such an 
approach have not yet been studied, and empirical demonstration 
of the feasibility of the process is first required. However, the per-
spective of enabling better estimation of individual PK on the desti-
nation concentrate is undoubtedly appealing. This is an example of 
a research project that could be performed with the rich WAPPS-
Hemo database that contains many hemophilia subjects who have 
switched between different factor concentrates.
5  | STUDY LIMITATIONS
The volume of literature we expected to find in this specific field 
was limited. As such, we have not registered the protocol or used 
the Peer Review of Electronic Search Strategies checklist when con-
ducting our search strategy. We cast a wide net with regards to our 
search terms, but we are aware that this will limit the internal and 
external validity of our results.
6  | CONCLUSION
Hemophilia treatment requires accurate and individualized dosing 
regimens to provide safe, effective, and cost-effective medication 
use. Although studies looking at bioequivalence/biosimilarity or 
assessing PK between 2 factor concentrates have led to PK com-
parisons, these studies lack the information required to predict 
an optimal dosing regimen for hemophilia patients starting on a 
new product. Studies that have examined the development of in-
hibitors did not mention the use of PK parameters to optimize a 
dosing regimen. As such, there exists no literature on the role or 
use of PK in optimizing factor concentrate dosing during product 
switching.
Given these limitations, further research is required to uti-
lize PK parameters from the origin product to predict the PK of 
the destination product in patients with hemophilia. Due to sim-
ilarity in PK parameters, especially across FVIII products,6 dose 
regimen predictability may be feasible using population PK meth-
ods and Bayesian forecasting. For example, standard-acting FVIII 
concentrates may be compared with other standard-acting FVIII 
concentrates and, in the same way, with newer long-acting FVIII 
concentrates.
With the introduction of newer and longer-acting concentrates, 
the use of PopPK methods will be an integral part in determining and 
predicting accurate dosing regimens for patients. The use of PopPK 
can change the current trial-and-error approach into a safer dosing 
regimen that makes use of prior PK knowledge to ensure patient 
safety and mindful resource consumption.
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TA B L E  5   Number of hemophilia patients from WAPPS-Hemo switching between FIX concentrates
FIX products
Switch to
TotalPlasma‐derived Recombinant
Recombinant 
glycoPEGylated
Recombinant Fc‐
fusion protein
Recombinant albumin 
fusion protein
Switch from Plasma-derived 4 1 0 11 1 17
Recombinant 0 1 1 22 7 31
Recombinant 
glycoPEGylated
0 0 0 0 0 0
Recombinant Fc-
fusion protein
1 0 1 0 5 7
Recombinant albu-
min fusion protein
0 0 0 1 0 1
Total 5 2 2 34 13 56
FIX, factor IX; WAPPS, Web-Accessible Population Pharmacokinetics Service.
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